Evidence review

Tesamorelin for Chemotherapy: Body Composition Evidence and Symptom Supports

Posted Jun 29, 2026 · Updated Jul 17, 2026 · 3 min read

What's breaking down

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why Tesamorelin might help you

Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.

Why Gabapentin / pregabalin matters for you

Drug: Gabapentin / pregabalin
What it does: Masks neuropathic pain signal; does not repair nerve.
Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

Tesamorelin → GH axis / visceral fat

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

Scientific sources catalogued (PubMed, trials, reviews): 3
Claims tagged human evidence: 4
Claims tagged preclinical (animal/lab): 0
Claims tagged anecdotal: 0
Reddit posts catalogued: 0
X posts catalogued: 0
Other anecdote sources (YouTube, Instagram, etc.): 0
Total sources in chain: 4

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.55 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin... meta-analysis (source s1)

2026 meta-analysis of RCTs in HIV lipodystrophy documenting VAT and lean mass changes.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin... meta-analysis

2026 meta-analysis of RCTs in HIV lipodystrophy documenting VAT and lean mass changes.

2026-06-29 23:25s1 · #422c8cd58aea

Gabapentinoids for chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis (source s2)

2024 meta-analysis concluding weak evidence for gabapentinoids in CIPN.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Gabapentinoids for chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis

2024 meta-analysis concluding weak evidence for gabapentinoids in CIPN.

2026-06-29 23:25s2 · #c014a678f4bd

Clinical Review Report: Tesamorelin (Egrifta) (source s3)

Health Canada/FDA review noting malignancy exclusion and IGF-1 concerns.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Clinical Review Report: Tesamorelin (Egrifta)

Health Canada/FDA review noting malignancy exclusion and IGF-1 concerns.

2026-06-29 23:25s3 · #4ccad405cd5b

Safety and limits

Tesamorelin trials excluded patients with active malignancy due to theoretical IGF-1 cancer promotion risk.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Evidence · 4 sources · swipe →chain 225fa93cdd1c · verify chain · provenance

1 / 4

PubMed.gov

Study

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin... meta-analysis

2026 meta-analysis of RCTs in HIV lipodystrophy documenting VAT and lean mass changes.

2026-06-29 23:25s1 · #422c8cd58aea

PubMed.gov

Study

Gabapentinoids for chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis

2024 meta-analysis concluding weak evidence for gabapentinoids in CIPN.

2026-06-29 23:25s2 · #c014a678f4bd

PubMed.gov

Study

Clinical Review Report: Tesamorelin (Egrifta)

Health Canada/FDA review noting malignancy exclusion and IGF-1 concerns.

2026-06-29 23:25s3 · #4ccad405cd5b

other

ClinicalTrials.gov search results for tesamorelin and chemotherapy/cancer

Absence of direct trials confirmed via registry search.

↗ clinicaltrials.gov

2026-06-29 23:25s4 · #225fa93cdd1c

Evidence ledger 5 · tier-ranked · API

human

Tesamorelin trials excluded patients with active malignancy due to theoretical IGF-1 cancer promotion risk.

sources: s3

human

A 2024 meta-analysis found limited evidence for gabapentinoids in preventing or treating chemotherapy-induced peripheral neuropathy.

sources: s2

humanlow confidence

Meta-analysis of RCTs showed tesamorelin reduced visceral adipose tissue by mean difference -27.71 cm² in HIV lipodystrophy patients.

sources: s1

humanlow confidence

Tesamorelin increased lean body mass by 1.42 kg (MD) in the same meta-analysis of HIV trials.

sources: s1

mechanisticlow confidence

No human trials of tesamorelin exist in chemotherapy patients.

sources: s4

Model review1 contributions · 1 modelExpand the recursive review layer

1 / 1

grok/grok-4.3writer

redraft2026-06-29 23:25

Tesamorelin for Chemotherapy: Body Composition Evidence and Symptom Supports · 5 claims · 4 sources

inspect — what it was prompted & output

prompted with

(default writer prompt)

input: Write a data-first, evidence-graded article: Tesamorelin for Chemo
Slug: tesamorelin-chemo
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_focus","condition":null,"condition_key":null,"primary_peptide":null,"peptides_in_scope":[{"id":"tesamorelin","name":"Tesamorelin"}],"drugs_in_scope":["gabapentin-lyrica"],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"What's breaking down","degen

it output

{
  "slug": "tesamorelin-chemo",
  "title": "Tesamorelin for Chemotherapy: Body Composition Evidence and Symptom Supports",
  "body": "## What's breaking down\n\nChemotherapy often disrupts multiple layers of physiology. One common pattern involves changes in body composition: loss of lean muscle (sarcopenia or cachexia) alongside shifts toward visceral fat accumulation in some patients. Another layer is nerve damage, where chemotherapy agents trigger peripheral neuropathy that produces pain, tingling, and reduced function. These changes can persist because repair processes in muscle, fat distribution, and nerves lag behind ongoing stress from treatment or recovery.\n\nTesamorelin is discussed in this context for its studied effects on the growth hormone (GH) axis and visceral fat. Gabapentin or pregabalin enters the picture for neuropathic symptoms. The sections below separate the layers each compound targets.\n\n## Why Tesamorelin might help you\n\n1. Tesamorelin stimulates the pituitary to release endogenous growth hormone, which acts on the GH/IGF-1 axis.\n2. In studied populations, this leads to measurable reductions in visceral adipose tissue area on CT scans.\n3. The same pathway supports modest increases in lean body mass.\n4. **Therefore for you:** If visceral fat gain or lean mass loss forms part of your post-chemo picture, the compound is discussed because it engages

74d099e823235eb4

Machine verification: /api/articles/tesamorelin-chemo/contributions

Ask this article · 7 suggested prompts

topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "Tesamorelin trials excluded patients with active malignancy due to theoretical IGF-1 cancer promotion risk."?

ask tesamorelin-chemo claim c4 · paste includes §SELF

What does the ledger say about this (human tier): "A 2024 meta-analysis found limited evidence for gabapentinoids in preventing or treating chemotherapy-induced peripheral neuropathy."?

ask tesamorelin-chemo claim c3 · paste includes §SELF

What does the ledger say about this (human tier): "Meta-analysis of RCTs showed tesamorelin reduced visceral adipose tissue by mean difference -27.71 cm² in HIV lipodystrophy patients."?

ask tesamorelin-chemo claim c1 · paste includes §SELF

What does the ledger say about this (human tier): "Tesamorelin increased lean body mass by 1.42 kg (MD) in the same meta-analysis of HIV trials."?

ask tesamorelin-chemo claim c2 · paste includes §SELF

What does the ledger say about this (mechanistic tier): "No human trials of tesamorelin exist in chemotherapy patients."?

ask tesamorelin-chemo claim c5 · paste includes §SELF

For my medical situation, what can you answer from your catalogue about Tesamorelin for Chemotherapy: Body Composition Evidence and Symptom Supports — and what would you need me to tell you first?

ask tesamorelin-chemo condition gaps · paste includes §SELF

What good and bad outcomes are documented for Tesamorelin for Chemotherapy: Body Composition Evidence and Symptom Supports (studies vs anecdotes)?

ask tesamorelin-chemo good bad experiences · paste includes §SELF

What's breaking down

Why Tesamorelin might help you

Why Gabapentin / pregabalin matters for you

How these fit together

What the evidence actually shows

What scientists say

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin... meta-analysis (source s1)

Gabapentinoids for chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis (source s2)

Clinical Review Report: Tesamorelin (Egrifta) (source s3)

Safety and limits

Connected articles

Related articles